CYMABAY THERAPEUTICS INC (CBAY) Stock Price, Quote, News and Overview
NASDAQ:CBAY - Nasdaq - US23257D1037 - Common Stock - Currency: USD
CBAY Quote, Performance and Key Statistics
32.48
+0.01 (+0.03%)
The current stock price of CBAY is 32.48 USD. In the past month the price increased by 0.96%. In the past year, price increased by 283.47%.
CBAY Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.58 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About CBAY
Company Profile
CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. The company is headquartered in Newark California, California and currently employs 60 full-time employees. The company went IPO on 2014-01-16. The firm is focused on developing therapies for patients with liver and other chronic diseases. The firm's lead product candidate, seladelpar, is a potent and selective agonist of peroxisome proliferator-activated receptor delta (PPARd), a nuclear receptor that regulates genes directly or indirectly involved in the synthesis of bile acids/sterols, metabolism of lipids and glucose, inflammation, and fibrosis. The company is focused on developing seladelpar for the treatment of primary biliary cholangitis (PBC), an autoimmune disease that causes progressive destruction of the bile ducts in the liver resulting in impaired bile flow (cholestasis) and inflammation. Its other product candidate, MBX-2982, targets G protein-coupled receptor 119 (GPR119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion.
Company Info
CYMABAY THERAPEUTICS INC
Suite 130, 7999 Gateway Blvd
Newark California CALIFORNIA 94560 US
CEO: Sujal Shah
Employees: 60
Company Website: https://www.cymabay.com/
Phone: 15102938800
CYMABAY THERAPEUTICS INC / CBAY FAQ
What is the stock price of CYMABAY THERAPEUTICS INC today?
The current stock price of CBAY is 32.48 USD. The price increased by 0.03% in the last trading session.
What is the ticker symbol for CYMABAY THERAPEUTICS INC stock?
The exchange symbol of CYMABAY THERAPEUTICS INC is CBAY and it is listed on the Nasdaq exchange.
On which exchange is CBAY stock listed?
CBAY stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CYMABAY THERAPEUTICS INC stock?
16 analysts have analysed CBAY and the average price target is 33.15 USD. This implies a price increase of 2.06% is expected in the next year compared to the current price of 32.48. Check the CYMABAY THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CYMABAY THERAPEUTICS INC worth?
CYMABAY THERAPEUTICS INC (CBAY) has a market capitalization of 3.73B USD. This makes CBAY a Mid Cap stock.
How many employees does CYMABAY THERAPEUTICS INC have?
CYMABAY THERAPEUTICS INC (CBAY) currently has 60 employees.
What are the support and resistance levels for CYMABAY THERAPEUTICS INC (CBAY) stock?
CYMABAY THERAPEUTICS INC (CBAY) has a support level at 32.44 and a resistance level at 32.49. Check the full technical report for a detailed analysis of CBAY support and resistance levels.
Is CYMABAY THERAPEUTICS INC (CBAY) expected to grow?
The Revenue of CYMABAY THERAPEUTICS INC (CBAY) is expected to decline by -62.23% in the next year. Check the estimates tab for more information on the CBAY EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CYMABAY THERAPEUTICS INC (CBAY) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CBAY, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CBAY, evaluating the profitability, health, valuation and growth aspects
- CYMABAY THERAPEUTICS INC (CBAY) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CYMABAY THERAPEUTICS INC (CBAY) Sales and EPS estimates to see what analysts future expectations are.
- CYMABAY THERAPEUTICS INC (CBAY) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CYMABAY THERAPEUTICS INC (CBAY) Insider and Institutional Ownership to learn about the owners and their transactions.
- CYMABAY THERAPEUTICS INC (CBAY) Stock Chart to make your own analysis
- CYMABAY THERAPEUTICS INC (CBAY) Latest news and press-releases to stay up to date.
Does CYMABAY THERAPEUTICS INC (CBAY) stock pay dividends?
CBAY does not pay a dividend.
When does CYMABAY THERAPEUTICS INC (CBAY) report earnings?
CYMABAY THERAPEUTICS INC (CBAY) will report earnings on 2024-05-13, after the market close.
What is the Price/Earnings (PE) ratio of CYMABAY THERAPEUTICS INC (CBAY)?
CYMABAY THERAPEUTICS INC (CBAY) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.97).
CBAY Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to CBAY. When comparing the yearly performance of all stocks, CBAY is one of the better performing stocks in the market, outperforming 98.73% of all stocks.
CBAY Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CBAY. CBAY scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
CBAY Financial Highlights
Over the last trailing twelve months CBAY reported a non-GAAP Earnings per Share(EPS) of -0.97. The EPS increased by 19.83% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -24.24% | ||
| ROE | -36.05% | ||
| Debt/Equity | 0.34 |
CBAY Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 54% to CBAY. The Buy consensus is the average rating of analysts ratings from 16 analysts.
For the next year, analysts expect an EPS growth of -50.27% and a revenue growth -62.23% for CBAY